Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00789373 · OUTCOME

Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer · Source last updated 2018-12-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)

Analysis population: All randomized participants

Groups in this outcome

Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed

pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care

Pemetrexed + Cisplatin Followed by Placebo

pemetrexed + cisplatin followed by placebo plus best supportive care

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed359
Pemetrexed + Cisplatin Followed by Placebo180

Reported measurements

Hospitalization due to Drug-related Adverse Event
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed8.4Not reportedNot reportedNot reportedNot reported
Pemetrexed + Cisplatin Followed by Placebo3.3Not reportedNot reportedNot reportedNot reported
Transfusions Packed Red Blood Cells
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed12.3Not reportedNot reportedNot reportedNot reported
Pemetrexed + Cisplatin Followed by Placebo4.4Not reportedNot reportedNot reportedNot reported
Transfusions Whole Blood
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed1.4Not reportedNot reportedNot reportedNot reported
Pemetrexed + Cisplatin Followed by Placebo0.6Not reportedNot reportedNot reportedNot reported
Transfusions Platelets
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed1.4Not reportedNot reportedNot reportedNot reported
Pemetrexed + Cisplatin Followed by Placebo0.6Not reportedNot reportedNot reportedNot reported
Transfusions Fresh Frozen Plasma
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed0Not reportedNot reportedNot reportedNot reported
Pemetrexed + Cisplatin Followed by Placebo0.6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        8.4
      2. group Id
        OG001
        value
        3.3
    title
    Hospitalization due to Drug-related Adverse Event
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        12.3
      2. group Id
        OG001
        value
        4.4
    title
    Transfusions Packed Red Blood Cells
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1.4
      2. group Id
        OG001
        value
        0.6
    title
    Transfusions Whole Blood
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1.4
      2. group Id
        OG001
        value
        0.6
    title
    Transfusions Platelets
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0.6
    title
    Transfusions Fresh Frozen Plasma
denoms
  1. counts
    1. group Id
      OG000
      value
      359
    2. group Id
      OG001
      value
      180
    units
    Participants
groups
  1. description
    pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care
    id
    OG000
    title
    Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed
  2. description
    pemetrexed + cisplatin followed by placebo plus best supportive care
    id
    OG001
    title
    Pemetrexed + Cisplatin Followed by Placebo
param Type
NUMBER
population Description
All randomized participants
reporting Status
POSTED
time Frame
Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
title
Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice